TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer

Oncogene

Volumn 28, Issue 49, 2009, Pages 4353-4363

  Szajnik, M ^a,b   Szczepanski, M J ^a,b   Czystowska, M ^a   Elishaev, E ^c   Mandapathil, M ^a   Nowak Markwitz, E ^b   Spaczynski, M ^b   Whiteside, T L ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

MyD88; Ovarian cancer; Paclitaxel; TLR4

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL GROWTH; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ONCOGENE C JUN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOPOLYSACCHARIDES; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; OVARIAN NEOPLASMS; PACLITAXEL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR CELLS, CULTURED; TUMOR ESCAPE; UP-REGULATION;

EID: 72049096882     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.289     Document Type: Article

References (49)

1. Backhed F, Hornef M. (2003). Toll-like receptor 4-mediated signaling by epithelial surfaces: necessity or threat? Microbes Infect 5: 951-959.
2. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, Carbonneil C, Misra N, Lepelletier Y et al. (2004). Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 101: 14210-14215.
3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG et al. (1987). Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418.
4. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA et al. (1999). Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10(Suppl 1): 87-92.
5. Blagosklonny MV, Fojo T. (1999). Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156.
6. Brewer MA, Johnson K, Follen M, Gershenson D, Bast Jr R. (2003). Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9: 20-30.
7. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. (2001). The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 31: 2448-2457.
8. Chuang T, Ulevitch RJ. (2001). Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 1518: 157-161.
9. Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S. (2004). Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta 1705: 103-120.
10. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. (2001). Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 81: 380-390.
11. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT et al. (2003). Overexpression of MAGE/GAGE genes in paclitaxel/doxor-ubicin-resistant human cancer cell lines. Clin Cancer Res 9: 2778-2785.
12. Duan Z, Feller AJ, Toh HC, Makastorsis T, Seiden MV. (1999). TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene 229: 75-81.
13. Eskan MA, Rose BG, Benakanakere MR, Lee MJ, Kinane DF. (2008). Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J Immunol 180: 1818-1825.
14. Fitzpatrick FA, Wheeler R. (2003). The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 3: 1699-1714.
15. Fukata M, Abreu MT. (2008). Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27: 234-243.
16. Gallardo D, Drazan KE, McBride WH. (1996). Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radio-sensitivity. Cancer Res 56: 4891-4893.
17. Girling JE, Hedger MP. (2007). Toll-like receptors in the gonads and reproductive tract: emerging roles in reproductive physiology and pathology. Immunol Cell Biol 85: 481-489.
18. He W, Liu Q, Wang L, Chen W, Li N, Cao X. (2007). TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44: 2850-2859.
19. Hefler LA, Grimm C, Ackermann S, Malur S, Radjabi-Rahat AR, Leodolter S et al. (2003). An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 63: 3066-3068.
20. Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch H. (1997). P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 143: 369-389.
21. Huang X, Barrett RP, McClellan SA, Hazlett LD. (2005). Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 46: 4209-4216.
22. Jordan MA, Wilson L. (2004). Microtubules as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
23. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D et al. (2004). Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37: 363-369.
24. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. (2001). Involvement of TLR4/MD-2 complex in species-specific lipopolysaccharide-mimetic signal transduction by Taxol. J Endotoxin Res 7: 232-236.
25. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. (2006). TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859-3868.
26. Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O et al. (2004). NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 166: 369-380.
27. Landen Jr CN, Birrer MJ, Sood AK. (2008). Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26: 995-1005.
28. Lauzon NM, Mian F, MacKenzie R, Ashkar AA. (2006). The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 241: 102-112.
29. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhat-naya L, Modugno F et al. (2006). Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 102: 244-251.
30. MacRedmond R, Greene C, Taggart CC, McElvaney N, O'Neill S. (2005). Respiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharide. Respir Res 6: 116.
31. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM et al. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556.
32. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. (2007). Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6: 609-621.
33. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning Jr RV et al. (1994). Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235-236.
34. Molteni M, Marabella D, Orlandi C, Rossetti C. (2006). Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 235: 75-83.
35. Penson RT, Kronish K, Duan Z, Feller AJ, Stark P, Cook SE et al. (2000). Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10: 33-41.
36. Petty R, Evans A, Duncan I, Kurbacher C, Cree I. (1998). Drug resistance in ovarian cancer-the role of p53. Pathol Oncol Res 4: 97-102.
37. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
38. Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP et al. (2003). Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 190: 61-72.
39. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. (2007). Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 178: 320-329.
40. Szczepanski M, Stelmachowska M, Stryczynski L, Golusinski W, Samara H, Mozer-Lisewska I et al. (2007). Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur Arch Otorhinolaryngol 264: 525-530.
41. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A et al. (2009). Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69: 3105-3113.
42. Takeda K, Akira S. (2007). TLR signaling. Sem Immunol 19: 24-32.
43. Takeda K, Kaisho T, Akira S. (2003). Toll-like receptors. Annu Rev Immunol 21: 335-376.
44. Takeuchi O, Kawai T, Sanjo H, Copeland NG, Gilbert DJ, Jenkins NA et al. (1999). TLR6: a novel member of an expanding toll-like receptor family. Gene 231: 59-65.
45. Tanimura N, Saitoh S, Matsumoto F, Akashi-Takamura S, Miyake K. (2008). Roles for LPS-dependent interaction and relocation of TLR4 and TRAM in TRIF-signaling. Biochem Biophys Res Commun 368: 94-99.
46. Taxman DJ, MacKeigan JP, Clements C, Bergstralh DT, Ting JP. (2003). Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/ extracellular signal-regulated kinase kinase inhibitor. Cancer Res 63: 5095-5104.
47. Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST et al. (2006). Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 25: 4857-4866.
48. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. (2003). Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19.
49. Zhang D, Zhang G, Hayden MS, Greenblatt MB, Bussey C, Flavell RA et al. (2004). A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303: 1522-1526.